Ascendis completes $60m series-D

Sofinnova, OrbiMed and Vivo Capital co-led the round, with co-investment provided by Janus Capital Management, Venrock, RA Capital Management, Rock Springs Capital and Sectoral Asset Management.

James Healy, Jonathan Silverstein and Albert Cha will join Ascendis's board of directors, representing Sofinnova, Orbimed and Vivo Capital, respectively.

The fresh capital will be used to fund product development and technology improvements for the company.

Previous funding
Ascendis Pharma raised a €17.6m series-A in 2007 in a round led by Gilde, Sofinnova and Technostart.

Sofinnova is the company's largest current shareholder.

Company
Ascendis develops pharmaceutical products for a broad range of treatments. The company uses proprietary technology that can be applied to new and existing therapies, which allows for predictable and sustained drug release in treatments.

Founded in 2007, the company is headquartered in Copenhagen, and maintains offices in Palo Alto, California and research and clinical development sites in Heidelberg and Copenhagen.

People
Jan Mikkelsen is the CEO of Ascendis. OrbiMed partner Jonathan Silverstein worked on the deal, as did Sofinnova managing partner Rafaèle Tordjman.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• Nordics
• Healthcare
• Denmark
• Gilde Investment Management
• Sofinnova Partners
• Sofinnova
• Unq2015Jan